contractpharmaMarch 18, 2021
Tag: Wuxi Biologics , Pfizer China , acquisition
WuXi Biologics has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China. The transaction is expected to close in the first half of 2021, which will immediately boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.
The state-of-the-art 50,000 sqaure meter facilities, GMP operational since 2018, includes DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10). Leveraging the facilities’ experienced workforce and WuXi Biologics’ extensive expertise in manufacturing and regulation, the production is expected to commence shortly after the deal closure.
“We are pleased to work with Pfizer and add the new Hangzhou biologics manufacturing facilities to our global network to address the surging manufacturing demands for late-stage and commercial projects due to the success of our Win-the-Molecule strategy,” said Chris Chen, chief executive officer, WuXi Biologics. “Globally DS and especially DP capacities are in urgent need now. The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world.”
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: